Completed PHASE2 INTERVENTIONAL NCT00046072

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis

Sponsor: Eisai Inc.

Conditions Infection Sepsis Sepsis Syndrome Septicemia Shock, Septic

Interventions E5564

Updated 5 times since 2017 Last updated: Dec 8, 2005 Started: Oct 31, 2001 Completion: Apr 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Infection and Sepsis, this trial is completed. The trial is conducted by Eisai Inc. and has accumulated 5 data snapshots since 2001. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Inc.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Buffalo, United States , Columbus, United States , Dallas, United States , Elk Grove, United States , Galveston, United States , Jacksonville, United States , Kansas City, United States , Manhasset, United States , Miami, United States and 7 more locations